DK1478373T3 - Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12 - Google Patents

Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12

Info

Publication number
DK1478373T3
DK1478373T3 DK02780174T DK02780174T DK1478373T3 DK 1478373 T3 DK1478373 T3 DK 1478373T3 DK 02780174 T DK02780174 T DK 02780174T DK 02780174 T DK02780174 T DK 02780174T DK 1478373 T3 DK1478373 T3 DK 1478373T3
Authority
DK
Denmark
Prior art keywords
tetrahydrofolic acid
tetrahydrofolic
vitamin
dosage units
tetrahydrofolate
Prior art date
Application number
DK02780174T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1478373T3 publication Critical patent/DK1478373T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK02780174T 2002-02-21 2002-11-15 Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12 DK1478373T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02075695 2002-02-21

Publications (1)

Publication Number Publication Date
DK1478373T3 true DK1478373T3 (da) 2007-01-15

Family

ID=27741182

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02780174T DK1478373T3 (da) 2002-02-21 2002-11-15 Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12

Country Status (29)

Country Link
US (1) US20050164977A1 (da)
EP (1) EP1478373B1 (da)
JP (1) JP5037779B2 (da)
KR (1) KR100936827B1 (da)
CN (1) CN1620302B (da)
AT (1) ATE341333T1 (da)
AU (1) AU2002343249B2 (da)
BR (1) BR0215613A (da)
CA (1) CA2476940C (da)
CR (1) CR7420A (da)
CY (1) CY1106273T1 (da)
DE (1) DE60215224T2 (da)
DK (1) DK1478373T3 (da)
EA (1) EA007599B1 (da)
EC (1) ECSP045305A (da)
ES (1) ES2274107T3 (da)
HK (1) HK1078780A1 (da)
HU (1) HUP0402674A3 (da)
IL (2) IL163579A0 (da)
ME (1) MEP37208A (da)
MX (1) MXPA04008185A (da)
NO (1) NO20043932L (da)
NZ (1) NZ534806A (da)
PL (1) PL209558B1 (da)
PT (1) PT1478373E (da)
RS (1) RS50909B (da)
UA (1) UA80965C2 (da)
WO (1) WO2003070255A1 (da)
ZA (1) ZA200407545B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
AU2013202756B2 (en) * 2006-07-06 2015-06-04 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
MX2009000256A (es) * 2006-07-06 2009-02-18 Bayer Schering Pharma Ag Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
GB0715502D0 (en) * 2007-08-08 2007-09-19 Univ Manchester Methods
JP2011511823A (ja) * 2008-02-13 2011-04-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト エストラジオール含有薬物の送達システム
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2324832B2 (de) * 2009-11-09 2016-11-30 Biogena Naturprodukte GmbH & Co KG Nahrungsergänzungsmittel bei Einnahme von hormonellen Kontrazeptiva
WO2012164095A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ES2925534T3 (es) * 2011-11-05 2022-10-18 South Alabama Medical Science Found Métodos, formulaciones y kits para reponer rápidamente los niveles de folato en mujeres
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
MX369035B (es) * 2013-12-12 2019-10-25 Donesta Bioscience B V Unidad de dosificacion solida de disolucion oral que contiene un componente de estetrol.
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
PE20231714A1 (es) 2015-06-18 2023-10-23 Estetra Sprl Unidad de dosificacion orodispersable que contiene un componente estetrol
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027764A1 (en) * 1996-01-31 1997-08-07 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
CA2261764A1 (en) * 1996-07-30 1998-02-05 Jeffrey B. Blumberg Dietary supplements
US6274564B1 (en) * 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
US6220453B1 (en) * 1998-04-07 2001-04-24 Fuji Photo Film Co., Ltd. Blood filter unit
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
AU4573899A (en) * 1998-06-19 2000-01-05 Beth Israel Deaconess Medical Center Dietary supplement for post-menopausal women
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
BG104880A (en) * 2000-10-24 2002-04-30 Иван ХРИСТОВ Medicamentous preparation for multiple sclerosis treatment

Also Published As

Publication number Publication date
KR100936827B1 (ko) 2010-01-14
AU2002343249B2 (en) 2009-02-05
PT1478373E (pt) 2007-01-31
MEP37208A (en) 2011-02-10
KR20040094711A (ko) 2004-11-10
HK1078780A1 (en) 2006-03-24
EA007599B1 (ru) 2006-12-29
PL209558B1 (pl) 2011-09-30
RS73304A (en) 2007-02-05
CA2476940A1 (en) 2003-08-28
DE60215224T2 (de) 2007-08-23
ES2274107T3 (es) 2007-05-16
CY1106273T1 (el) 2011-10-12
EP1478373A1 (en) 2004-11-24
BR0215613A (pt) 2004-12-07
ATE341333T1 (de) 2006-10-15
RS50909B (sr) 2010-08-31
DE60215224D1 (de) 2006-11-16
CN1620302B (zh) 2011-04-27
US20050164977A1 (en) 2005-07-28
AU2002343249A1 (en) 2003-09-09
EA200401014A1 (ru) 2006-10-27
HUP0402674A2 (hu) 2005-04-28
CA2476940C (en) 2011-11-01
IL163579A0 (en) 2005-12-18
MXPA04008185A (es) 2004-11-26
JP5037779B2 (ja) 2012-10-03
CN1620302A (zh) 2005-05-25
WO2003070255A1 (en) 2003-08-28
HUP0402674A3 (en) 2012-12-28
JP2005523283A (ja) 2005-08-04
ZA200407545B (en) 2006-06-28
PL371441A1 (en) 2005-06-13
UA80965C2 (en) 2007-11-26
IL163579A (en) 2011-03-31
CR7420A (es) 2006-02-06
NZ534806A (en) 2006-05-26
ECSP045305A (es) 2004-10-26
NO20043932L (no) 2004-11-19
EP1478373B1 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
DK1478373T3 (da) Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12
CN101489563A (zh) 用于避孕和预防先天性畸形风险的药物制剂
AU739544B2 (en) The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for the influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
WO1999053910A2 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US20080268048A1 (en) Pharmaceutical composition for contraception and for reducing the risk of congenital abnormalities
CA2696030A1 (en) Use of gestagens in combination with (6s)-5-methyltetrahydrofolate for therapy of endometriosis with simultaneous reduction of therapy side effects and reduction of the risk of congenital abnormalities at the onset of a pregnancy
EP1891959A1 (de) Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
ES1286975U (es) Comprimido que contiene 25-OH vitamina D3
CZ88297A3 (cs) Farmaceutický přípravek na bázi transdermálního emulgelu s obsahem jednoho nebo více hormonů, jakož i způsob jeho výroby